Teva Pharmaceutical Industries Ltd.

Director's Dealing • Mar 6, 2024

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Francis Richard D.	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 10% Owner Director
(Last) (Middle) (First) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 03/03/2024	Officer (give title below) Other (specify below) President and CEO
(Street) Tel Aviv, L3 6944020 (City) (State) (Zip)	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Transaction	12A. Deemed	3. Transaction					4. Securities Acquired (A) 5. Amount of Securities Beneficially	6	7. Nature
(Instr. 3)	Date	Execution Date, if Code			or Disposed of (D)			Owned Following Reported	Ownership of Indirect
	(Month/Day/Year) any		(Instr. 8)		(Instr. 3, 4 and 5)			Transaction(s)	Form:	Beneficial
		(Month/Day/Year)						(Instr. 3 and 4)		Direct (D) Ownership
						(A)			or Indirect (Instr. 4)
						Or			(1)
			Code		Amount	(D)	Price		(Instr. 4)
Ordinary Shares (1)	03/03/2024		M		67,231	ત	(2)	154,356	D
'Ordinary Shares (1)	03/04/2024		द (3)		31,061 (4)	D	S 13.3373 (5)	123,295	D

1. Title of Derivative Security (Instr. 3)	Conversion Date Price of Derivative Security	3. Transaction or Exercise (Month/Day/Year) any	3A. Deemed Execution Date, if Transaction Derivative (Month/Day/Year) (Instr. 8)	4. Code	5. Number of Securities Acquired (Month/Day/Year) (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Security (Instr. 5)	8. Price of 9. Number of Derivative Derivative Securities Beneficially Owned Following	10 Form of Security: Direct (D)	11. Nature Ownership of Indirect Beneficial Derivative Ownership (Instr. 4)
				Code	(A)	(D)	Date Exercisable Date	। Expiration Title		Amount or Number of Shares		Reported Transaction(s) (1) (Instr. 4)	l or Indirect (Instr. 4)
Restricted Share Units	(2)	03/03/2024		M		67,231	(6)	(6)	Ordinary Shares (1)	67,231	\$ 0	201,693	D
Restricted Share Units	(2)	03/04/2024		A	200,892		(7)	(7)	Ordinary Shares (1)	200,892	\$ 0	200,892	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. . puts. calls. warrants. options. convertible securities)

Explanation of Responses:

• 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
• 1. Each resiried share unit represents a comment, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash vale of one ordinary share.
• 1. The transaction reported in this Form 4 was effected pursuant to a Rule 105-1 trading plan adopted by the reporting person on November 13, 2023.
• 1. Represents the number of shares required to be sold o cover tax withodding obligations in comection with the vesting of the resting of the resting of the resting of the re
• 1. The price reported in Column 4 is a weighted avere sold in multiple transactions at prices ranging from \$1.2.5 to \$1.445 inclusive. The reporting proson undertake to provide, upon request by the SEC staff, the issuer, foll information regarding the number of shares sold at each separate price.
• 1. Restricted share units were granted on March 3, 2023, with 67,2024, March 3, 2024, March 3, 2025, March 3, 2027,
• 1. Restricted share units were granted on March 4, 2024, with 50,223 vesting on each of March 4, 2026, March 4, 2028,

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis 03/05/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly.

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information in this form are not required to respond unless the form displays a currently wild OMB Number.